Skip to Main Content

Paper Details

Clinical validation of the tempus xT next-generation targeted oncology sequencing assay.
Oncotarget
111
2019
cell lines, gene fusion, hematologic malignancies, indels, single nucleotide variants, solid tumors, transcriptome RNA, tumor, whole
Author NameAffiliation
Robert HuetherTempus Labs Inc.
Robert HuetherTempus Labs Inc.
Kevin P WhiteTempus Labs Inc.
  • 1 - 3

Datasets

Release 1.2